We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Immune effector cells induced by complete Freund's adjuvant exert an inhibitory effect on antigen-specific type 2 T helper responses.
Clinical and Experimental Allergy 1997 March
BACKGROUND: It has been well documented that environmental factors such as antigenpresenting cells and related cytokines could affect the development of T helper cells.
OBJECTIVE: The purpose of this study is to investigate the effect of different adjuvants on T cell development.
METHODS: Ovalbumin (OVA) combined with aluminum hydroxide (Alum) plus pertussis toxin (PT) or complete Freund's adjuvant (CFA) were used to sensitize mice; the production of IgG and IgE anti-OVA antibodies was then followed. In addition, OVA-specific proliferative responses and cytokine production by spleen cells were also investigated.
RESULTS: The data showed that the adjuvants themselves could modify the pattern of immune response: (1) IgG2a anti-OVA antibody was higher in mice sensitized with OVA + CFA compared to that of mice sensitized with OVA + Alum + PT; (2) the ratio of IFN-gamma/IL-4 produced by OVA-stimulated spleen cells was higher in mice sensitized with OVA + CFA than that of mice sensitized with OVA + Alum + PT: (3) increased percentage of gamma delta T cells was noted in the peritoneal exudate cells of OVA + CFA immunized mice; and (4) the immune response of mice sensitized with OVA + Alum + PT was inhibited by the adoptively transferred ascitic cells from OVA + CFA immunized mice.
CONCLUSION: In general, the data suggested higher IgG2a and the ratio of IFN-gamma/IL-4 was noted in mice sensitized with OVA + CFA. Further elucidation of the regulatory mechanism of allergen-specific T helper cells development and exploration of possible agents for immunotherapy might shed light on the management of atopic diseases.
OBJECTIVE: The purpose of this study is to investigate the effect of different adjuvants on T cell development.
METHODS: Ovalbumin (OVA) combined with aluminum hydroxide (Alum) plus pertussis toxin (PT) or complete Freund's adjuvant (CFA) were used to sensitize mice; the production of IgG and IgE anti-OVA antibodies was then followed. In addition, OVA-specific proliferative responses and cytokine production by spleen cells were also investigated.
RESULTS: The data showed that the adjuvants themselves could modify the pattern of immune response: (1) IgG2a anti-OVA antibody was higher in mice sensitized with OVA + CFA compared to that of mice sensitized with OVA + Alum + PT; (2) the ratio of IFN-gamma/IL-4 produced by OVA-stimulated spleen cells was higher in mice sensitized with OVA + CFA than that of mice sensitized with OVA + Alum + PT: (3) increased percentage of gamma delta T cells was noted in the peritoneal exudate cells of OVA + CFA immunized mice; and (4) the immune response of mice sensitized with OVA + Alum + PT was inhibited by the adoptively transferred ascitic cells from OVA + CFA immunized mice.
CONCLUSION: In general, the data suggested higher IgG2a and the ratio of IFN-gamma/IL-4 was noted in mice sensitized with OVA + CFA. Further elucidation of the regulatory mechanism of allergen-specific T helper cells development and exploration of possible agents for immunotherapy might shed light on the management of atopic diseases.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app